The Clinical Coding and Schedule Development (CCSD) develops and maintains procedural and diagnostics nomenclature for private payers in England. Once codes are added to the Schedule, a private insurance company can develop reimbursement tariff for these procedures and tests.
The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in August:
- Thermography (MI047)
- Mole mapping (MI048)
- Hyperferritinemia - cataract testing (OP041)
- Mycobacteria genotype ID (5025T)
- Hereditary neuropathy with liability to pressure palsies (5026B)
- Minimal residual disease (5027B)
- Urine pheuma antibody (5028U)
- Ferroportin SLC40A1 gene sequencing (5029B)
- Thromboelastometry (5030B)
- O(6)-Methylguanine-DNA methyltransferase (MGMT) gene (5031T)
- 18 Gene panel glycogon storage (5032B)
- Zinc transport 8 (5033B)
- RH5 (5034B)
- Calcium corrected (5035B)
- Otoblot-inner ear antigen (5036B)
- PROP profile (5037B)
- AMA autoantibodies (5038B)
- SMA autoantibodies (5039B)
- Neurone specific enolase (NSE) (5040B)
- C. difficile ribotyping (5041F)
- C. difficile PCR (5042F)
- Faecal multiplex PCR (5043F)
- Staphylococcus PVL testing (5044S)
- SKAB: skin antibodies (5045B)
- Measles, mumps and rubella antibodies (5046B)
- ANTI-AMPA 1/2 antibodies (5047B)
- MPL mutation (5048B)
- Serum free light chains (5049B)
- T cell clonality (5050M)
- Beta D glucan (5051T)
- C-MYC FISH (5052M)
- CYP21A2 gene sequencing (5053B)
- G6PD gene deficiency gene test (5054B)
- Hydrocortisone test (5055B)
- Abelson murine leukaemia oncogene testing (5056B)
- Mismatch repair protein MMR (5057T)
See full information here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.